Prokinetic agents: Current aspects with focus on cisapride

Annals of Gastroenterology

Volumn 13, Issue 4, 2000, Pages 269-289

  Georgiadis, G T ^a   Markantonis Kyroudis, Sophia ^a   Triantafillidis, J K ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b Saint Panteleimon General State Hospital   (Greece)

Author keywords

Drug interactions; Gastrointestinal hypomotility; Pharmacodynamics; Pharmacokinetics; Prokinetic agents; Side effects

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATROPINE; BETHANECHOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; DIAZEPAM; DICYCLOVERINE; DIGOXIN; DISOPYRAMIDE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; LEVODOPA; LITHIUM; MACROLIDE; METOCLOPRAMIDE; MORPHINE; NALOXONE; OCTREOTIDE; OPIATE ANTAGONIST; PARACETAMOL; PROKINETIC AGENT; SOMATOSTATIN DERIVATIVE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACETYLCHOLINE RELEASE; ALLERGIC REACTION; ANTIEMETIC ACTIVITY; AREA UNDER THE CURVE; BREAST HYPERPLASIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME INHIBITION; ESOPHAGUS MOTILITY; FATIGUE; GALACTORRHEA; GASTRIC DYSMOTILITY; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERPLASIA; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MENSTRUATION DISORDER; NAUSEA; NERVE STIMULATION; NEUROTRANSMITTER RELEASE; PH; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; QT DISPERSION; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH EMPTYING; STOMACH PARESIS; STRESS; VOMITING; XEROSTOMIA;

EID: 34548354534     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Brunton Lawrence: Prokinetic agents in: Agents affecting gastro - intestinal water flux and motility in: Goodman and Gilman's: The Pharmacological Basis Of Therapeutics, 9th edition, Mc Graw-Hill, 1996.
2. Wiseman LR, Faulds D. Cisapride: An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47 (1):116-152.
3. Mc Callum RW, Prakash C, Campoli-Richards M, Goa KL. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use as a prokinetic agent in gastrointestinal motility disorders, Drugs 1988; 36:652-681.
4. Mc Callum RW. Review of the current-status of prokinetic agents in gastroenterology. Am J Gastroenterology 1985; 80:1008-1016.
5. Reynolds JC. Prokinetic agents: A key in the future of gastroenterology. Gastroenterol. Clin North Am 1989; 18:437-457.
6. Reynolds J. Challenges in the treatment of colonic motility disorders. Am J Health - Syst Pharm 1996; 53(3): 17-26.
7. Reynolds JC, Putnam PE. Prokinetic agents. Gastroenterol Clin North Am 1992; 21:567-596.
8. Longo W, Vernava A. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum 1993; 36(7):696-708.
9. Graham JR. Cisapride for severe non ulcer dyspepsia, pseudoobstruction and constipation. Med J Austr 1989; 150:667.
10. Singh P, Santella R, Zawada E. Gastrointestinal prokinetic agents for enhanced drug response in gastroparesis. Am J Health Syst Pharm 1997; 54:2609-2612.
11. Furness J, Bornstein J. The enteric nervous system and its extrinsic connections in: Textbook of Gastroenterology, Tadataka Yamada editor, 2d edition, Philadelphia, Lippincott 1995.
12. Mc Callum RW, Fink SM, Lerner E. Effects of meitoclopramide and betanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterology 1983; 84:1573.
13. Gattuso J, Kamm M. Adverse effects of drugs used in the management of constipation and diarrhea. Drug Safety 1994; 10(1):47-65.
14. Konturek SJ. Opiates and the gastrointestinal tract. Am J Gastroenterol 1980; 74:285-291.
15. Kreek MJ, Schaefer RA, Hahn EF, Fishman J. Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet 1983; 1:261-262.
16. Katz MD, Erstad BL. Octreotide, a new somatostatin analogue. Clin Pharm 1989; 8:255-273.
17. Lux G, Femppel J, Lederer P, Rosch W, Domschke W. Somatostatin induces interdigestive motor and secretory complex-like activity in man. Gastroenterology 1980; 78:A1212.
18. Stanley M, Lautin A, Rotrosen J, Gershon S, Kleinberg D. Metoclopramide: Antipsychotic efficacy of a drug lacking potency in receptor models. Psychopharmacology 1980; 71:219-225.
19. Wallin L, Boesby S, Madsen T. Effect of metoclopramide on oesophageal peristalsis and gastro-oesophageal sphincter pressure. Scand J Gastroenterol 1979; 14:923-927.
20. Reyntjens A, Verlinden M, Aerts T. Development and clinical use of the new gastrointestinal prokinetic drug cisapride (R 51 619). Drug Development Research 1986; 8:251-265.
21. Niemegeers CJE, Schellekens KHL, Janssen PAJ. The antiemetic effects of domperidone, a novel potent gastrokinetic. Arch Int Pharmacodyn Ther 1980; 244:130-140.
22. Costall B, Fortune DH, Naylar R.J. Neuropharmacological studies on the neuroleptic potential of domperidone (R 33812). J Pharm Pharmacol 1979; 31:344-347.
23. Brogden RN, Carmine AA, Heel RC. Domperidone: A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982; 24:360-400.
24. Schuurkes JA, Van Neuten JM, Van Daele PG. Domperidone improves myogenically transmitted antroduodenal coordination by blocking D.A. receptor sites. Scand J Gastroenterol 1984; 96:101-110.
25. Chey WY, Lee KY, You CH, Shah AN, Hamilton DL. Effect of cisapride on colonic transit time in dogs and humans. Dig Dis Sci 1984; 29:562.
26. Cucchiara S. Cisapride therapy for gastrointestinal disease. J Pediart Gastroenterol Nutr 1996; 22:259-269.
27. Farup PG, Hordenak N, Wetterhus S, Lange OJ, Horde O, Tronstad R. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998; 33:128-131.
28. Tack J, Coremans G, Janssens J. A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders. Drug Safety 1995; 12(6):384-392.
29. Borne R. Serotonin: The Neurotransmitter for the 90's. Drug Topics, 108, 1994.
30. 4 receptors? Eur J Pharmacol 1992; 212(1):51-59.
31. Taniyama K, Nakayama S, Takeda K, Matsuyama S, Shirikawa J. Cisapride stimulates motility of the intestine via the 5-hydroxy tryptamine receptors. J Pharmacol Exp Ther 1991; 258:1098-1104.
32. 4 receptors in guinea-pig ascending colon. Eur J Pharmacol 1991; 196:149-155.
33. Van Neuten JM, Reyntjens A, Schuurkes JAJ. Gastrointestinal motility stimulating properties of the non-anti-dopaminergic, non-cholinergic compound R 51 619. Gastroenterol. Clin Biol 1983; 7:706.
34. Reyntjens A, Verlinden M, De Coster R, Janisch HD, Smout A, De Cree J, Leempoels J, Verhaegen HG. Clinical pharmacological evidence for cisapride's lack of antidopaminergic or direct cholinergic properties. Curr Ther Res 1984;. 36:1045-1052.
35. Nemeth PR, Ort C.A, Zafirov DH. Interactions between serotonin and cisapride on myenteric neurons. Eur J Pharmacol 1985; 166:387-391.
36. 1234 receptors. J Pharmacol Exp Ther 1993; 264:79-88.
37. Koop H, Monnikes H, Koop I, Dionysius J, Schwarz C, Arnold R. Effect of the prokinetic drug cisapride on gastrointestinal hormone 'release. Scand J Gastroenterol 1986; 21:907-913.
38. Cucchiara S, Stajano A, Boccieri A, De Stefano M, Capozzi C. Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease. Gut 1990; 31:21-25.
39. Inauen W, Emda C, Weber B, Armstrong D, Bettschen HU. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24-hour ambulatory combined pH and manometry study. Gut 1993; 34:1025-1031.
40. Van Daele L, De Cuypere A, Van Kerckhove M. Routine radiological follow through examination shows effect of cisapride on gastrointestinal transit: A controlled study. Curr Ther Res 1984; 36:1038-1044.
41. Testoni PA, Bagnolo F, Fanti L, Passaretti S, Tittobello A. Long-term oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients. Gut 1990; 31:286-290.
42. Robertson CS, Evans DF, Ledingham SJ, Atkinson M. Cisapride in the treatment of gastro-oesophageal reflux disease. Alim Pharm Ther 1993; 7:181-190.
43. Champion MC, Gulenchyn K, Braeten J, Irvine P, O' Leary T. Cisapride is effective therapy in the management of diabetic gastroparesis. J Gastroenterol Hepatol 1989; 4(Suppl. 3):25.
44. Patel R, Launspach J, Saffer E. Effects of cisapride on salivary production in normal subjects. Dig Dis Sci 1996; 41:480-484.
45. Hatlebakk Berstad: Treatment of Gastro-Oesophageal Reflux Disease. Clin Pharmacokinetics 1996; 31:386-406.
46. Honghui Zhou, Herron J, Clyde C, Lee P, Mechlinski W, Luana Pesco- Koplowitz: Pharmacokinetic profile of cisapride 20 mg after once and twice daily dosing. Clin Ther 1998; 20:292-298.
47. Hedner T, Hedner J, Gelin-Friberg A, Huang ML, Van de Poel S: Comperative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers. Eur J Clin Pharmacol 1990; 38:629-631.
48. Meuldermans W, Van Peer A, Hendrickx J, Lauwers W, Swysen E. Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 1988; 16:403-409.
49. Davies DS, Mills FJ, Welburn PJ. Cisapride has no effect on antipyrine clearance. Br J Clin Pharmacol 1988; 26:808-809.
50. Rowbotham DJ, Milligan K, Mc Hugh P. Effect of single doses of cisapride and ranitidine administered simultaneously on plasma concentrations of cisapride and ranitidine. Br J Anaesth 1991; 67:302-305.
51. Bedford T. and Rowbotham D. Cisapride: Drug interactions of clinical significance. Drug Safety 1996; 15:167-175.
52. Finet L, Westeel PF, Hary L. Effects of cisapride on the intestinal absorption of cyclosporine in renal transplant recipients. Gastroenterology 1991; 100:A 209.
53. Rowbotham DJ, Milligan K, Mc Hugh P. Effect of cisapride on morphine absorption after oral administration of sustained release morphine. Br J Anaesth 1991; 67:421-425.
54. Daneshmend TK, Mahida YR, Bhaskar N. Does cisapride alter the anticoagulant effect of warfarin? A pharmacodynamic assessment. The World Congress of Gastroenterology. Aug. 26-31, Sydney, P.D. 169, 1990.
55. Moening H, Wesermeyer D, Gaska T. The effect of metoclopramide and cisapride on the pharmacokinetics of phenprocoumon. Eur J Clin Pharmol 1989; 36 (Suppl): P.A.117.
56. Jonker JJC. The effect of cisapride on anticoagulant treatment with acenocoumarol. Janssen Pharmaceuticals, Clinical Research Report No: R 51619-N.L, Aug.1985.
57. Rowbotham DJ, Parncacott S, Nimmo WS. No effect of cisapride on paracetamol absorption after oral simultaneous administration. Eur J Clin Pharmacol 1992; 42:235-236.
58. Rowbotham DJ, Nimmo WS. Effect of cisapride on morphine-induced delay in gastric emptying. Br J Anaesth 1987; 59:536-539.
59. Rowbotham DJ, Bamber PA, Nimmo WS. Comparison of the effect of cisapride and metoclopramide on morphine-induced delay in gastric emptying. Br J Clin Pharmacol 1988; 26:741-746.
60. Kluger MT, Plummer JL, Owen H. The influence of rectal cisapride on morphine-induced gastric stasis. Anaesth Intensive Care 1991; 19:346-350.
61. Bateman DN. The action of cisapride on gastric emptying and the pharmacokinetics of oral diazepam. Eur J Clin Pharmacol 1986; 30:205-208.
62. Kirch W, Janisch HD, Santos SR. Effect of cisapride and metoclopramide on digoxin bioavailability. Eur J Drug Metab Pharmacokinet 1986; 11:249-250.
63. Diaz-Neira W, Sanchez V, Mena MA, Garcia Justo de Yebenes. The effects of cisapride on plasma L-Dopa levels and clinical response in Parkinson's disease. Movement Disorders 1995; 10(1):66-70.
64. Van der Kleijn E, Van Mameren C. Effect of cisapride on the plasma concentrations of a delayed formulation of propranolol and on the clinical effects on blood pressure in mildly hypertensive patients. Janssen Pharmaceuticals, Clinical Research Report No: 46957, 1989.
65. Roberts GW, Kowalski SR, Calabretto JP. Lack of effect of cisapride on phenytoin free fraction. Ann Pharmacother 1992; 26:1016-1017.
66. Song CW, Um SH, Kim CD, Ryu H S, Hyun JH, Choe JG. Double-blind placebo controlled study of cisapride in patients with nonspecific esophageal motility disorder accompanied by delayed esophageal transit. Scand J Gastroenterol 1997; 32:541-546.
67. Blum AL, Adami B, Bouzo MH, Brondstatter G, Fumagalli I. Effects of cisapride on relapse of esophagitis. Dig Dis Sci 1993; 38:551-560.
68. Eggleston A, Wigerinck A, Huijghegabaert S, Dubois D, Haycox A. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: A clinical database analysis. Gut 1998; 42(1).
69. Tilley NJ. Non-ulcer dyspepsia in: Textbook of Gastroenterology, 2d edition, T. Yamada editor, Philadelphia, Lippincott, p. 1446-1455, 1995.
70. Talley NJ. Non-ulcer dyspepsia: myths and realities. Aliment Pharmacol Ther 1991; 5, Suppl. 1:145-162.
71. Mc Quaid Kenneth: Dyspepsia in: Symptoms and signs of gastrointestinal disease in: Current Medical Diagnosis and Treatment, Lawrence Tierney, Stephen J. Mc Phee and Maxine A. Papadakis editors, Lange, 1999.
72. Friedman Lawrence, Isselbacher Kurt J. Indigestion in: Harrison's Principles of Internal Medicine, 14th edition, 1998.
73. Functional Dyspepsia in: The Merck Manual, 17th edition, p. 236-237, 1999.
74. Everhart JE editor: Digestive Diseases in the United States: Epidimiology and Impact: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington D.C.: U.S. Government Printing Office, 1994: N.I.H. publication no 94-1447.
75. Talley NJ. Functional dyspepsia-should treatment be targeted' on disturbed physiology? Aliment Pharmacol Ther 1995; 9:107-115.
76. 2 blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994; 343:811-816.
77. Chung JM. Cisapride in chronic dyspepsia: results of a double-blind placebo-controlled trial. Scand J Gastroenterol 1993; 28(Suppl. 195):11-14.
78. De Nutte N, Van Ganse W, Witterhulge M, Defrance P. Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride. Clin Therap 1989; 11:62-68.
79. Cucchiara S, Bortolotti M, Boccieri A, De Stefano M, Di Nola M. Effects of cisapride on antro-duodenal motility and on duodeno-gastric reflux in children with functional dyspepsia. Ital J Gastroenterol 1989; 21:372.
80. Marzio L, Di Felice F, Laico MG, Imbimbo B, Lapenna D. Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptoms. A double-blind placebo-controlled clinical trial with cisapride. Dig Dis Sci 1992; 37:262-267.
81. Agorastos I, Akriviadis E, Goulis G. Effect of cisapride in nonulcer dyspepsia: A placebo controlled trial. Cur Ther Res 1991; 49:870-877.
82. Hausken T, Berstad A. Cisapride treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol 1992; 27:213-217.
83. Wood SF, Penney SC, Cochran KM. Cisapride in functional dyspepsia: a double-blind placebo-controlled randomized trial in general practice patients. Scand J Gastroenterol 1993; 28:5-10.
84. Van Outryve M, De Nutte N, Van Eaghem P, Garis JP. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. Scand J Gastroenterol 1993; 28:47-53.
85. Archimandritis A, Tzivras M, Fertakis A, Emmanuel A, Laoudi F. Cisapride, metoclopramide and ranitidine in the treatment of severe nonulcer dyspepsia. Clin Therap 1992; 14:553-561.
86. Fumagalli I, Hammer B. Cisapride versus metoclopramide in the treatment of functional dyspepsia-a double blind comperative trial. Scand J Gastroenterol, 1993.
87. Sabbatini F, Minieri M, Monzi G, Piai G, D' Angelo V. Clinical efficacy and safety of cisapride and clebopride in the management of chronic functional dyspepsia: A double-blind, randomized study. Ital J Gastroenterol 1991; 23:1-4.
88. Miazza B, Holter F, Brignoli R. A multicentric comperative trial in functional dyspepsia: cisapride versus cimetidine. Gastroenterol 1993; 104:A18.
89. Lewin-van De Broek NT, Buskens E, Smout AJPM, de Wit NJ, Verheij TJM, Numans ME. Treatment of dyspepsia in primary care: current symptom-based strategy, omeprazole and cisapride are equally effective. Gut 1999; 45(Suppl. V):A88.
90. Tatsuta M, Ishi H, Nakaizumi A, Okuda S. Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Alim Pharmac Ther 1992; 6:221-228.
91. Verhaeghe J, Jaecques N, Rombouts J, Spoepen W, Cardon E. Functional dyspepsia versus other functional gastrointestinal disorders: A practical approach in Belgian general practices. Scand J Gastroenterol 1993; 28: 25-35.
92. Inoue M, Sekiguchi T, Harasawa S, Miwa T, Miyoshi A. Dyspepsia and dyspepsia subgroups in Japan: symptom profiles and experience with cisapride. Scand J Gastroenterol 1993; 28:36-39.
93. Heyse PM, Rambaldo R, Hazellhoff B. Factors affecting short-and long-term outcome of a short therapeutic trial with cisapride in dyspeptic patients. Scand J Gastroenterol 1993; 28:15-24.
94. Fehr HF. Risk factors, co-medication and concomitant diseases: their influence on the outcome of therapy with cisapride. Scand J Gastroenterol 1993; 28(195):40-46.
95. Champion MC, Braeten J, Gulenchyn K. Domperidone compared to cisapride in the management of gastroparesis. Am J Gastroenerol 1991; 86:1309.
96. Tollesson PO, Cassuto J, Rimback G, Faxen A, Bergman L, Mattsson E. Treatment of post-operative paralytic ileus with cisapride. Scand J Gastroenterol 1991; 26:477-482.
97. Loening-Baucke V. Chronic constipation in children. Gastroenterology 1993; 105:1557-1564.
98. Coremans G, Ventrappen C. Does cisapride improve longstanding intractable constipation? Digestion 1986; 24:137-160.
99. Macoll C, Mc Cannell KL, Baylis B. Treatment of acute colonic pseudo-obstruction (Ogilvie's syndrome) with cisapride. Gastroenterology 1990; 98:773-776.
100. Testoni PA, Bagnolo F, Masci E, Toti G, Spinelli A. Efficacy of cisapride in gastric ulcer: results of a double-blind randomized trial versus ranitidine and versus cisapride plus ranitidine. J Clin Gastroenterol 1993; 17:5-9.
101. Koletzko S, Corey M, Ellis L, Soino M, Stringer DA, Durie PR. Effects of cisapride in patients with cystic fibrosis and distal intestinal obstruction syndrome. J Pediatr 117:815-822.
102. Pillans PI, Wood SM. Cisapride increases micturition frequency. J Clin Gastroenterol 1994; 19:336-346.
103. Nolan P. Cisapride and brittle asthma. Lancet 1990; 336:1443.
104. Olsson S, Edwards IR. Tachycardia during cisapride treatment. Br Med J 1992; 305:748-749.
105. Inman W, Kubota K. Tachycardia during cisapride treatment. Br Med J 1992; 305:1019.
106. Wysowski D, Bacsauyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335:290-291.
107. "Dear Doctor" letter, Janssen-Cilag pharmaceutica research foundation, June 26, 1998.
108. Arabehety JT, Leitao OR, Fassler S, Olarte M, Serrano C. Cisapride and metoclopramide in the treatment of gastro-oesophageal reflux disease. Clin Therap 1998; 10:421-428.
109. Horn JR, Anderson GD. Stability of an extremporaneously compounded cisapride suspension. Clin Therap 1994; 16: 169-172.
110. Wager E, Tooley PJH, Pearce GL, Wilton LV, Mann RD. A comparison of two cohort studies evaluating the safety of cisapride: Prescription-Event Monitoring and a large phase IV study. Eur J Clin Pharm. 1997; 52:87-94.